Tue January 19, 2021 - Northeast Edition
MyCentralJersey.com
A rendering of the proposed $750 million Rutgers Cancer Institute of New Jersey Cancer Pavillion, which would be built on the site of Lincoln Annex School. (DEVCO rendering)
The New Brunswick, N.J., city planning board has approved the construction of the state s first free-standing cancer hospital, a focal point of a $750 million project.
The application submitted by Cancer Pavilion Redevelopment Associates LLC, an affiliate of New Brunswick Development Corporation, or DEVCO, to construct the 11-story, 519,000-sq.-ft. Rutgers Cancer Institute of New Jersey Pavilion passed by a unanimous vote the week of Jan. 11.
Credit: SWOG Cancer Research Network
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.
Results of the SWOG study, led by Scott Kopetz, MD, PhD, of M.D. Anderson Cancer Center, are published in the
Journal of Clinical Oncology. The findings are expected to change the standard of care for patients with colorectal cancer that is metastatic - when tumors spread to other parts of the body - and includes a mutation in the BRAF gene called V600E. This mutation is found in about 10 percent of metastatic colorectal cancers and tumors with the mutation rarely responds to treatment, resulting in
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
Older patients with Hodgkin s lymphoma historically have inferior outcomes relative to their younger counterparts.
Individuals age 60 and over, who make up about 20% of the overall population, often have higher rates of advanced-stage disease at presentation. Comorbidities and decreased organ function may make them less likely to tolerate chemotherapy as well.
There s even evidence to suggest that Hodgkin s lymphoma has a different biology in this older group, with higher rates of mixed cellularity subtype and Epstein-Barr virus-associated disease. Furthermore, lower response and cure rates, as well as a greater risk of treatment-related death, have been reported with standard multi-agent regimens.
When it comes to treating older patients, geriatric assessments are a good place to start, said Andrew Evens, DO, MSc, of Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute of New Jersey.
Vacuna inhalada induce una respuesta inmune rápida en ratones eluniversal.com.mx - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eluniversal.com.mx Daily Mail and Mail on Sunday newspapers.